Clinical research of PRP combined with autologous bone grafting in treatment of bone defect
DONG Haijiao1, SHEN Guodong2, HAO Yan3, DU Aicui1, DU Bin1
1. Transfusion Department, Characteristics Medical Center of PLA Rocket Army , Beijing 100088, China; 2. Transfusion Department, Qinhuai District, General Hospital of Eastern Theater Command, Nanjing 210002, China; 3. Orthopedics Department, Characteristics Medical Center of PLA Rocket Army, Beijing 100088, China
Abstract：Objective To evaluate the therapeutic effect of platelet-rich plasma (PRP) combined with autologous bone grafting in the treatment of bone defect and its influence on bone repair. Methods Sixty patients with bone defect admitted to Characteristics Medical Center of PLA Rocket Army from January 2023 to December 2023 were selected as the research subjects, and were divided into two groups according to the random number table method, the experimental group (30 cases) and the control group (30 cases). The experimental group was treated with PRP combined with autologous bone grafting, while the control group was treated with simple autologous bone grafting. The two groups were compared in terms of bone healing time, bone healing rate, bone density, bone strength, bone morphology scoring, LEFS scoring, and VAS scoring. Multivariate linear regression and multivariate logistic regression analyses were used to identify factors influencing bone healing. Results The experimental group showed significantly better outcomes in terms of bone healing time, bone healing rate, bone density, bone strength, and bone morphology scoring compared with the control group, with statistically significant differences (P<0.05), and no serious postoperative complications occurred. Multivariate regression analysis indicated that PRP treatment was an independent influencing factor for bone healing time and bone healing rate (P<0.05). Conclusions PRP combined with autologous bone grafting is a safe, effective, and feasible treatment for bone defect, which can promote the healing and repair of bone defect, improve the quality of bone healing, and enhance patients' quality of life.
董海蛟, 沈国栋, 郝岩, 杜爱翠, 杜彬. 富含血小板血浆联合自体骨移植治疗骨缺损的临床研究[J]. 武警医学, 2024, 35(6): 506-510.
DONG Haijiao, SHEN Guodong, HAO Yan, DU Aicui, DU Bin. Clinical research of PRP combined with autologous bone grafting in treatment of bone defect. Med. J. Chin. Peop. Armed Poli. Forc., 2024, 35(6): 506-510.
Buchan P G, Rimland B. Def ining the Diamond[M]. Washington DC: Center for Strategic and International Studies, 2020.
[4]
Oliva F, Migliorini F, Cuozzo F, et al. Outcomes and complications of the reamer irrigator aspirator versus traditional iliac crest bone graft harvesting: a systematic review and meta-analysis[J]. J Orthop Traumatol, 2021, 22: 1-13.
[5]
Jamal M S, Hurley E T, Asad H, et al. The role of Platelet Rich Plasma and other orthobiologics in bone healing and fracture management: A systematic review[J]. J Clin Orthop Trauma, 2022, 25: 101759.
[6]
Zhang Y, Xing F, Luo R, et al. Platelet-rich plasma for bone fracture treatment: a systematic review of current evidence in preclinical and clinical studies[J]. Front Med, 2021, 8: 676033.
[7]
Yausep O E, Madhi I, Trigkilidas D. Platelet rich plasma for treatment of osteochondral lesions of the talus: A systematic review of clinical trials[J]. J orthop, 2020, 18: 218-225.
[8]
Costa L A V, Lenza M, Irrgang J J, et al. How does platelet-rich plasma compare clinically to other therapies in the treatment of knee osteoarthritis? A systematic review and meta-analysis[J]. Am J Sport Med, 2023, 51(4): 1074-1086.
[9]
Tang S, Wang X, Wu P, et al. Platelet‐rich plasma vs autologous blood vs corticosteroid injections in the treatment of lateral epicondylitis: a systematic review, pairwise and network meta‐analysis of randomized controlled trials[J]. PM R, 2020, 12(4): 397-409.
[10]
Gupta S, Paliczak A, Delgado D. Evidence-based indications of platelet-rich plasma therapy[J]. Expert Rev Hematol, 2021, 14(1): 97-108.
[11]
Everts P A, van Erp A, DeSimone A, et al. Platelet rich plasma in orthopedic surgical medicine[J]. Platelets, 2021, 32(2): 163-174.
[12]
Fermín T M, Calcei J G, Della Vedova F, et al. Review of Dohan Eherenfest et al.(2009) on" Classification of platelet concentrates: From pure platelet-rich plasma (P-PRP) to leucocyte-and platelet-rich fibrin (L-PRF)"[J]. J ISAKOS, 2023, S2059-7754 (23) 00545-X.
[13]
Fang J, Wang X, Jiang W, et al. Platelet-rich plasma therapy in the treatment of diseases associated with orthopedic injuries[J]. Tissue Eng Part B-Re, 2020, 26(6): 571-585.
[14]
Gupta S, Paliczak A, Delgado D. Evidence-based indications of platelet-rich plasma therapy[J]. Expert Rev Hematol, 2021, 14(1): 97-108.
[15]
Andersen C, Wragg N M, Shariatzadeh M, et al. The use of platelet-rich plasma (PRP) for the management of non-union fractures[J]. Curr Osteoporos Rep, 2021, 19: 1-14.
[16]
Miron R J, Zhang Y. Autologous liquid platelet rich fibrin: A novel drug delivery system[J]. Acta Biomater, 2018, 75: 35-51.
[17]
Talebi Ardakani M R, Meimandi M, Shaker R, et al. The effect of platelet-rich fibrin (PRF), plasma rich in growth factors (PRGF), and enamel matrix proteins (Emdogain) on migration of human gingival fibroblasts[J]. J Dent, 2019, 20(4): 232-239.
[18]
Kramer M J E, Keaney T C. Systematic review of platelet-rich plasma (PRP) preparation and composition for the treatment of androgenetic alopecia[J]. J Cosmet Dermatol, 2018, 17(5): 666-671.
[19]
Anitua E, Zalduendo M M, Prado R, et al. Morphogen and proinflammatory cytokine release kinetics from PRGF-Endoret fibrin scaffolds: evaluation of the effect of leukocyte inclusion[J]. J Biomed Mater Res A, 2015, 103(3): 1011-1020.
2024, Vol. 35 
